Myriad Genetics (MYGN) Tops Q3 EPS by 1c, Beats on Revenue; Offers FY25 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. SMCI
8. RTX
9. S
10. COF

Go back to Myriad Genetics (MYGN) Tops Q3 EPS by 1c, Beats on Revenue; Offers FY25 Guidance

Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution

November 3, 2025 4:05 PM EST

Highlights

Third quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds1 of $8.1 million, consistent with management expectations.Third quarter 2025 hereditary cancer testing revenue and volume grew 3% and 11% year-over-year, respectively. Third quarter... More